ENGN

Conviction 13HealthcareScan · Mon, Aug 10, 2026

ENGN$1.75-2.78%

ResistanceSupportVol 14

Vol MA14 600.5K

May 11May 28Jun 16Jul 6Jul 23Aug 10

enGene Therapeutics Inc.BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)www.engene.com ↗

Price1.75

Change-2.78%

Gap-2.22%

Rel volume1.06×

Avg volume657.31K

Avg $ vol1.21M

SMA 201.82

SMA 501.78

SMA 2006.18

Price vs 50-1.81%

Price vs 200-71.67%

MA stackbearish

50/200 cross—

Supertrenddown · 2.00

RSI (14)41

MACD hist0.01

MACD cross—

Stoch %K / %D17 / 32

ADX (14)7

+DI / −DI17 / 19

RSI divergence—

MACD divergence—

ATR %+5.24%

ADR %4.74%

52w high12.17

52w low1.44

From 52w high-85.62%

Above 52w low+21.53%

New 52w highNo

SqueezeOn · 37d

Bollinger width12.44%

%B0.18

Donchian pos16.00%

Donchian high1.96

Donchian low1.71

AVWAP (52w high)3.01

vs AVWAP high-41.94%

AVWAP (52w low)1.73

vs AVWAP low+0.91%

OBV trendUp

Chaikin MF (20)-0.03

Today vs 20d1.06×

Avg vol (14d)600.5K

Avg vol (20d)657.31K

Avg $ vol (20d)1.21M

Market cap—

RS 3m (vs SPY)-1.05%

RS 6m (vs SPY)-93.80%

RS line new highNo

Trend template0/8

Technical rank8.8

1 week-1.13%

1 month-7.89%

3 months+16.67%

6 months-81.68%

1 year-50.98%

YTD-80.23%

P/E-1.02

P/B0.47

P/S—

P/FCF-1.19

EPS2.29

Div yield—

ROE-45.97%

ROA-38.14%

Debt/Eq—

Current12.57

EV/EBITDA-0.73

Gross margin—

Net margin—

Rev growth—

EPS growth-112.73%

Price target—

Target upside—

Analyst rating—

Institutional—

Ent. value90.08M

Revenue—

Net income-30.23M

Gross profit—

Free cash flow-100.72M

IndustryBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

ExchangeNasdaq

Shares out—

Employees82

ListedWed, Nov 1, 2023

Free float—

Float %—

Short interest—

Days to cover—

Short volume—

Squeeze score—

Next earnings—

EPS forecast—

Last EPS vs est—

Last surprise—

Setup gradeD

Conviction13 / 100

Pattern quality—

Tech rank8.8 / 100

Group rank86 / 100 · Leading

Status laneNo active setup

Setup direction—

Pattern family

Resistance1.95

Support1.70

Days since event—

Candle confirm—

News sentiment—

Financials as of Thu, Apr 30, 2026 · quarterly.

Congress activity

Disclosed STOCK Act trades in ENGN

All disclosures →

No recent disclosed trades by Congress in ENGN. STOCK Act filings can lag the trade by up to 45 days.

Insider activity

SEC Form 4 transactions in ENGN · 2 buys

Insider	Side	Shares	Value	Traded	Filed
Astley-Sparke Philip Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31K	—	2026-06-16	2026-06-17
BRUNK GERALD A Director · Stock Option (Right to Buy) · 2026-06-16	Grant	31K	—	2026-06-16	2026-06-17

SEC filings

EDGAR filings in ENGN · 7 recent

EDGAR →

Get daily signals & real-time alerts.

StockSetups scans ~12,300 US stocks & ETFs after every close and sorts every long setup into four ranked lanes — each with a trade plan — plus an always-on engine firing 35+ real-time intraday alerts. Free for 14 days, cancel in one click.

Start free — 14-day full access →

Educational data, not financial advice. Patterns, levels and the trade plan are algorithmic, not a recommendation to trade.